Osisko Gold Royalties: What Happened In Q3?

Summary

  • Osisko Gold Royalties Ltd's Q3 results show a net loss attributed to a non-cash impairment charge and operational challenges at a diamond mine.
  • Despite the loss, Osisko's production and revenues remain within guidance, indicating stability.
  • The company's strategic acquisitions and partnerships position it for future growth and diversification in the gold and copper sectors.

Lemon_tm

Data by YCharts

As a major holding in our The Gold Bull Portfolio, Osisko Gold Royalties Ltd (NYSE:OR) demands our attention, especially following its latest Q3 results.

In my last public coverage on August 24, I highlighted the positive outlook

Osisko's Q3 Results and Financial Overview

Was Q3 really that bad?

Osisko GR

  • Gold equivalent ounces earned: 23,292 (down only slightly from 23,850 in Q3 2022).

  • Cash flows from operations: $43.5 million (down from $51.1 million in Q3 2022).

  • Adjusted earnings: $22.4 million, or $0.12 per basic share (down from $25.8 million, or $0.14 per basic share in Q3 2022).

Bullish corporate moves

Osisko's Namdini royalty is a premier asset. (Osisko GR)

Osisko's Financial Health: A Closer Look

Future Outlook: Bright Prospects Ahead

Osisko's growth outlook remains the best in the industry. (Osisko GR)

Osisko's updated valuation

Osisko shares look undervalued. (Osisko GR)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

  • Top
  • Latest
empty
No comments yet